Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer

References

• Ferlay J Shin HR Bray F Forman D Mathers C Parkin DM Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 2010 127 12 2893 2917 21351269
   PubMed Web of Science ®Google Scholar
• Hann CL Rudin CM Management of small-cell lung cancer: incremental changes but hope for the future Oncology (Williston Park, NY) 2008 22 13 1486 1492
   Web of Science ®Google Scholar
• Kalemkerian G P Akerley W Bogner P Small cell lung cancer J Natl Compr Canc Netw 2013 11 1 78 98 23307984
   PubMed Web of Science ®Google Scholar
• Murray N Turrisi AT A review of first-line treatment for small-cell lung cancer J Thorac Oncol 2006 1 3 270 278 17409868
   PubMed Web of Science ®Google Scholar
• Govindan R Page N Morgensztern D Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 2006 24 28 4539 4544 17008692
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE Gore EM Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms Oncologist 2010 15 2 187 195 20145192
   PubMed Web of Science ®Google Scholar
• Kurata T Okamoto I Tamura K Fukuoka M Amrubicin for non-small-cell lung cancer and small-cell lung cancer Invest New Drugs 2007 25 5 499 504 17628745
   PubMed Web of Science ®Google Scholar
• Kimura T Kudoh S Hirata K Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride Clin Med Insights Oncol 2011 5 23 34 21499556
   PubMedGoogle Scholar
• Shah CM Amrubicin: a synthetic anthracyclin analogue in the treatment of extensive stage small cell lung cancer Recent Pat Anticancer Drug Discov 2009 4 3 241 245 19538159
   PubMed Web of Science ®Google Scholar
• Hanada M Mizuno S Fukushima A Saito Y Noguchi T Yamaoka T A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex Jpn J Cancer Res 1998 89 11 1229 1238 9914793
   PubMedGoogle Scholar
• Morisada S Yanagi Y Noguchi T Kashiwazaki Y Fukui M Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts Jpn J Cancer Res 1989 80 1 69 76 2496061
   PubMedGoogle Scholar
• Noda T Watanabe T Kohda A Hosokawa S Suzuki T Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs Invest New Drugs 1998 16 2 121 128 9848575
   PubMed Web of Science ®Google Scholar
• Salvatorelli E Menna P Surapaneni S Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin J Pharmacol Exp Ther 2012 341 2 464 473 22338033
   PubMed Web of Science ®Google Scholar
• Salvatorelli E Menna P Gonzalez Paz O Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin J Pharmacol Exp Ther 2012 341 2 474 483 22338034
   PubMed Web of Science ®Google Scholar
• Yamaoka T Hanada M Ichii S Morisada S Noguchi T Yanagi Y Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells Jpn J Cancer Res 1998 89 10 1067 1073 9849587
   PubMedGoogle Scholar
• Frederick CA Williams LD Ughetto G Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin Biochemistry 1990 29 10 2538 2549 2334681
   PubMed Web of Science ®Google Scholar
• Fornari FA Randolph JK Yalowich JC Ritke MK Gewirtz DA Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells Mol Pharmacol 1994 45 4 649 656 8183243
   PubMed Web of Science ®Google Scholar
• Pigram WJ Fuller W Hamilton LD Stereochemistry of intercalation: interaction of daunomycin with DNA Nature New Biol 1972 235 53 17 19 4502404
   PubMedGoogle Scholar
• Minotti G Menna P Salvatorelli E Cairo G Gianni L Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 2004 56 2 185 229 15169927
   PubMed Web of Science ®Google Scholar
• Okamoto I Hamada A Matsunaga Y Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer Cancer Chemother Pharmacol 2006 57 3 282 288 16028099
   PubMed Web of Science ®Google Scholar
• Hamada A [Development of an individualized therapy for establishing the optimal dosage by the pharmacokinetics profiles of anticancer agents.] Yakugaku Zasshi 2005 125 8 631 637 Japanese 16079613
   PubMed Web of Science ®Google Scholar
• Kimura T Kudoh S Mitsuoka S Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities Anticancer Drugs 2009 20 6 513 518 19352172
   PubMed Web of Science ®Google Scholar
• Matsunaga Y Hamada A Okamoto I Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients Ther Drug Monit 2006 28 1 76 82 16418698
   PubMed Web of Science ®Google Scholar
• Makino Y Yamamoto N Sato H Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer Cancer Chemother Pharmacol 2012 69 4 861 869 22042514
   PubMed Web of Science ®Google Scholar
• Tani N Yabuki M Komuro S Kanamaru H Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride Xenobiotica 2005 35 12 1121 1133 16418065
   PubMed Web of Science ®Google Scholar
• Nagata M Kimura T Suzumura T C609T polymorphism of NADPH quinone oxidoreductase 1 correlates clinical hematological toxicities in lung cancer patients treated with amrubicin Clin Med Insights Oncol 2013 7 31 39 23467445
   PubMedGoogle Scholar
• Takakuwa O Oguri T Ozasa H C609T polymorphism of NAD(P) H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin J Thorac Oncol 2011 6 11 1826 1832 21964527
   PubMed Web of Science ®Google Scholar
• Kitagawa C Saka H Kajikawa S Mori K Oki M Suzuki R Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial Cancer Chemother Pharmacol 2012 69 5 1379 1385 22237957
   PubMed Web of Science ®Google Scholar
• Ohe Y Negoro S Matsui K Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer Ann Oncol 2005 16 3 430 436 15653702
   PubMed Web of Science ®Google Scholar
• Fukuda M Nakamura Y Kasai T Nagasaki Thoracic Oncology Group A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer J Thorac Oncol 2009 4 6 741 745 19404211
   PubMed Web of Science ®Google Scholar
• Inoue A Ishimoto O Fukumoto S A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405 Ann Oncol 2010 21 4 800 803 19825887
   PubMed Web of Science ®Google Scholar
• Asakuma M Yamamoto M Wada M Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer Cancer Chemother Pharmacol 2012 69 6 1529 1536 22415148
   PubMed Web of Science ®Google Scholar
• Onoda S Masuda N Seto T Thoracic Oncology Research Group Study 0301 Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301 J Clin Oncol 2006 24 34 5448 5453 17135647
   PubMed Web of Science ®Google Scholar
• Inoue A Sugawara S Yamazaki K Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402 J Clin Oncol 2008 26 33 5401 5406 18854562
   PubMed Web of Science ®Google Scholar
• Kaira K Sunaga N Tomizawa Y A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer Lung Cancer 2010 69 1 99 104 19853960
   PubMed Web of Science ®Google Scholar
• Ettinger DS Jotte R Lorigan P Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer J Clin Oncol 2010 28 15 2598 2603 20385980
   PubMed Web of Science ®Google Scholar
• Jotte R Conkling P Reynolds C Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy J Clin Oncol 2011 29 3 287 293 21135284
   PubMed Web of Science ®Google Scholar
• O’Brien ME Konopa K Lorigan P Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062 Eur J Cancer 2011 47 15 2322 2330 21684151
   PubMed Web of Science ®Google Scholar
• Hirose T Nakashima M Shirai T Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer Lung Cancer 2011 73 3 345 350 21277039
   PubMed Web of Science ®Google Scholar
• Jotte R von Pawel J Spigel DR Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC) 2011 American Society of Clinical Oncology Annual Meeting Proceedings (Post-Meeting Edition) June 3–7, 2011 Chicago, Illinois 29 No 15_suppl May 20 Supplement 2011 7000
   Google Scholar
• Kotani Y Satouchi M Ando A A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of extended-stage small cell lung cancer (ED-SCLC) 2012 American Society of Clinical Oncology Annual Meeting Proceedings (Post-Meeting Edition) June 1–5, 2012 Chicago, Illinois 30 No 15_suppl May 20 Supplement 2012 7003
   Google Scholar
• Kobayashi M Matsui K Iwamoto Y West Japan Oncology Group Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301 JThorac Oncol 2010 5 7 1075 1080 20479694
   PubMed Web of Science ®Google Scholar
• Noro R Yoshimura A Yamamoto K East Japan Chesters Group Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer Anticancer Res 2013 33 3 1117 1123 23482789
   PubMed Web of Science ®Google Scholar
• Hata A Katakami N Fujita S Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancer Lung Cancer 2011 72 2 224 228 20828862
   PubMed Web of Science ®Google Scholar
• Ettinger DS Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific? J Thorac Oncol 2007 2 2 160 165 17410034
   PubMed Web of Science ®Google Scholar
• Abidin AZ Garassino MC Califano R Harle A Blackhall F Targeted therapies in small cell lung cancer: a review Ther Adv Med Oncol 2010 2 1 25 37 21789124
   PubMedGoogle Scholar
• Zhan J Han Q Wang K Development of antibody therapeutics for small cell lung cancer Expert Opin Investig Drugs 2013 22 2 235 244
   PubMed Web of Science ®Google Scholar
• Scott AM Wolchok JD Old LJ Antibody therapy of cancer Nat Rev Cancer 2012 12 4 278 287 22437872
   PubMed Web of Science ®Google Scholar
• Mullard A Maturing antibody-drug conjugate pipeline hits 30 Nat Rev Drug Discov 2013 12 5 329 332 23629491
   PubMed Web of Science ®Google Scholar